Telomir Pharmaceuticals, Inc. Common Stock Market Cap ($62.59 Million)
Market Cap & Net Worth: Telomir Pharmaceuticals, Inc. Common Stock (TELO)
Telomir Pharmaceuticals, Inc. Common Stock market cap. Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ:TELO) has a market capitalization of $62.59 Million ($62.59 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20824 globally and #4722 in its home market, demonstrating a -8.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Telomir Pharmaceuticals, Inc. Common Stock's stock price $0.91 by its total outstanding shares 68774956 (68.77 Million). Also see cash flow conversion of Telomir Pharmaceuticals, Inc. Common Sto for how efficiently the company converts equity into cash flow.
Telomir Pharmaceuticals, Inc. Common Stock Market Cap History (2024–2026)
Telomir Pharmaceuticals, Inc. Common Stock market cap history from 2024 to 2026. Data shows change from $296.43 Million to $62.59 Million (-52.51% CAGR). Check Telomir Pharmaceuticals, Inc. Common Sto (TELO) stock price for real-time trading data and today's change.
Index Memberships
Telomir Pharmaceuticals, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #588 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1988 of 3165 |
Weight: Telomir Pharmaceuticals, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Telomir Pharmaceuticals, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Telomir Pharmaceuticals, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Telomir Pharmaceuticals, Inc. Common Sto annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TELO by Market Capitalization
Companies near Telomir Pharmaceuticals, Inc. Common Stock in the global market cap rankings as of November 4, 2026. Also see Telomir Pharmaceuticals, Inc. Common Sto asset portfolio for a full breakdown of the balance sheet.
Key companies related to Telomir Pharmaceuticals, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Telomir Pharmaceuticals, Inc. Common Stock (2024–2026)
Market capitalization of Telomir Pharmaceuticals, Inc. Common Stock from 2024 to today. Between 2024 and today, Telomir Pharmaceuticals, Inc. Common Stock's market cap moved from $296.43 Million to $ 62.59 Million, with a yearly change of -52.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $62.59 Million | -31.58% |
| 2025 | $91.47 Million | -69.14% |
| 2024 | $296.43 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Telomir Pharmaceuticals, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $62.59 Million USD |
| MoneyControl | $62.59 Million USD |
| MarketWatch | $62.59 Million USD |
| marketcap.company | $62.59 Million USD |
| Reuters | $62.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macu… Read more